|
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors. |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Lilly |
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Birdie (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Syndax (Inst) |
Travel, Accommodations, Expenses - Asana Biosciences |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma; Ascentage Pharma |
Leadership - Ascentage Pharma; Ascentage Pharma |
Stock and Other Ownership Interests - Ascentage Pharma; Ascentage Pharma |
|
|
Employment - Ascentage Pharma; Guangzhou Healthquest Pharma |
Leadership - Ascentage Pharma; Guangzhou Healthquest Pharma |
Stock and Other Ownership Interests - Ascentage Pharma; Guangzhou Healthquest Pharma |